Trial · NCT07200583
Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
NCT07200583, Completed, Ting YANG
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients. Trials, record NCT07200583. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07200583
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
- NCT number
- NCT07200583
- Status
- Completed
- Enrollment
- 50 participants, actual
- Lead sponsor
- Ting YANG
- Conditions
- Hematologic Malignancies, Hematologic Disorders, Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Graft Failure
- Interventions
- Protein A immunoadsorption, Rituximab (optional, in some patients), Bortezomib (optional, in some patients)
- First posted
- 2025-10-01
- Last updated
- 2025-11-18
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hematopoietic engraftment success rate | Within 28 days after transplantation | Proportion of patients achieving engraftment after haploidentical HSCT, defined as: Neutrophil recovery ≥0.5 × 10\^9/L for 3 consecutive days; Platelet recovery ≥20 × 10\^9/L without transfusion for 3 consecutive days |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07200583
GET https://conductscience.org/api/trials/v1/NCT07200583/registered